TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04704323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP-100
Description: CAP-100 (humanized antibody against C-C-chemokine receptor 7 \[CCR\]7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP-100
Description: CAP-100 (humanized antibody against C-C-chemokine receptor 7 \[CCR\]7)
Study: NCT06561568

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Conventional physical therapy protocol for chondromalacia patellae consist of stretches to warm up and cool down Resistance training ,in which patient will perform each exercise for 3 sets of 10 repetitions. Each repetition will be given with a 10 second hold.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: Conventional physical therapy protocol for chondromalacia patellae consist of stretches to warm up and cool down Resistance training ,in which patient will perform each exercise for 3 sets of 10 repetitions. Each repetition will be given with a 10 second hold.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Kinesio tape will be applied on Vastus medialis Oblique and around the patella.~• Frequency: 3 times a week for 4 weeks.
Study: NCT05600010

Intervention type: OTHER
Intervention: Microplastics
Description: Detection of microplastics as a yes/no value
Study: NCT06445855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal relationship-based intervention program
Description: An interpersonal relations-based intervention program will be implemented with an online intervention platform.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interpersonal relationship-based intervention program
Description: An interpersonal relations-based intervention program will be implemented with an online intervention platform.
Study: NCT05120232

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unified Protocol
Description: A transdiagnostic, cognitive behavioral therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Unified Protocol (UP+)
Description: A transdiagnostic, cognitive behavioral therapy.
Study: NCT04692688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX3330
Description: APX3330, a small-molecule oral tablet, is a Ref-1 inhibitor that can potentially reduce proinflammatory and hypoxic signaling that contributes to several eye diseases.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets are identical to APX3330 tablets except for the absence of the active pharmaceutical ingredient.
Study: NCT06133166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG017 ointment
Description: Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG017 ointment
Description: Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG017 ointment
Description: Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EG017 ointment placebo
Description: Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EG017 ointment placebo
Description: Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
Study: NCT05905718

Intervention type: OTHER
Intervention: assessment
Description: Assessments of thoracic kyphosis angle, balance performance, and gait performance.

Intervention type: OTHER
Intervention: assessment
Description: Assessments of thoracic kyphosis angle, balance performance, and gait performance.
Study: NCT06468579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT20029
Description: Stage 1: GT20029 gel single ascending dose (1mg, 2mg, 5mg, 10mg) with 14 days washout window; Multi ascending dose (2mg QD, 2mg Q12h, 5mg QD, 5mg Q12h,10mg QD) for 14 consecutive days; Stage 2: GT20029 solution multi ascending dose (5mg QD, 10mg QD, 20mg QD) for 14 consecutive days;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GT20029 matching placebo
Description: Stage 1: GT20029 gel matching placebo single ascending dose (1mg, 2mg, 5mg, 10mg) with 14 days washout window; Multi ascending dose (2mg QD, 2mg Q12h, 5mg QD, 5mg Q12h,10mg QD) for 14 consecutive days; Stage 2: GT20029 solution matching placebo multi ascending dose (5mg QD, 10mg QD, 20mg QD) for 14 consecutive days;
Study: NCT04681131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAB-AXL-ADC
Description: Conditionally active biologic anti-AXL antibody drug conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAB-AXL-ADC
Description: Conditionally active biologic anti-AXL antibody drug conjugate
Study: NCT05886686

Intervention type: DEVICE
Intervention: Validation of the accuracy of a combined oximeter, thermometer and heart rate measurement device
Description: Validation of the combined device measurements compared with standard of care devices

Intervention type: DEVICE
Intervention: Validation of the accuracy of a combined oximeter, thermometer and heart rate measurement device
Description: Validation of the combined device measurements compared with standard of care devices
Study: NCT04786574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan (OPC-41061)
Description: Tolvaptan suspension will be administered orally or via nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 2 years.
Study: NCT04716309

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction and volar locking plate and closed reduction and K-wires.
Description: DVR Anatomic Plate, K-wires

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction and volar locking plate and closed reduction and K-wires.
Description: DVR Anatomic Plate, K-wires
Study: NCT04681131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: PD-1 inhibitor
Study: NCT06236217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carotid Ultrasound
Description: The carotid artery corrected flow time (FTc) was used in patients to optimize the volume status before performing spinal anesthesia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical cardiometry
Description: Stroke volume variation (SVV) measured by electrical cardiometry (EC) was used to optimize the volume status before performing spinal anesthesia.
Study: NCT06380140

Intervention type: PROCEDURE
Intervention: Open Tension-free Inguinal Hernia Repair
Description: A blood sample is taken the day after surgery
Study: NCT06508983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG301 Injection
Description: Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SG301 placebo
Description: Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pomalidomide
Description: Dosage form: capsule Route of administration: oral Dosage: 4 mg Frequency: once daily on Days 1 through 21 of each 28-day cycle.
Study: NCT05444673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paprizumab combined with cisplatin and 5-FU
Description: Patients with advanced temporal bone cancer were treated with pabulizumab combined with cisplatin and 5-FU
Study: NCT06508983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Dosage form: capsule Route of administration: oral Dosage: 4 mg Frequency: once daily on Days 1 through 21 of each 28-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexamethasone
Description: Dosage form: tablets or solution for infusion Route of administration: oral or intravenous Dosage: 40 mg (participants with BMI \< 18.5 kg/m2 received 20 mg dexamethasone) Frequency: once daily on Day 1, 8, 15, 22 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dosage form: tablets or solution for infusion Route of administration: oral or intravenous Dosage: 40 mg (participants with BMI \< 18.5 kg/m2 received 20 mg dexamethasone) Frequency: once daily on Day 1, 8, 15, 22 of each 28-day treatment cycle.
Study: NCT05570422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRC-01
Description: KRC-01 is a solution that contains hydrogen peroxide 3% with sodium hyaluronate 1%. Hydrogen peroxide is the active ingredient for this radiosensitizer.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: * Target definition for EBRT will be based on 3D imaging by computed tomography, positron emission tomography with computed tomography, or MRI.~* Intensity-modulated radiotherapy (IMRT) must be used.~* IMRT should be given once daily Monday-Friday, 5 fractions per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: * Weekly concomitant cisplatin (40 mg/m2) during EBRT~* Neo-adjuvant chemotherapy or other forms of antineoplastic treatment apart from weekly concomitant cisplatin (40 mg/m2) are not allowed.~* Adjuvant chemotherapy (after completion of EBRT+BT) is not allowed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: * BT treatment planning will be based on 3D-image-guided BT by MRI.~* Low-dose-rate, pulsed-dose-rate, or high-dose-rate BT
Study: NCT05004285

Intervention type: DRUG
Group type: OTHER
Intervention: [F-18]Florastamin
Description: A single dose of \[F-18\]Florastamin at 10 ± 1 mCi is IV administered at Visit 2, and \[F-18\]Florastamin PET/CT images are obtained from the head to thigh after 110 ± 10 minutes.
Study: NCT05875480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: synchronized telerehabilitation
Description: In the synchronized telerehabilitation group, the exercise program of the first 2 weeks was submitted via Albert Health Assistant application and patients were asked to do these exercises regularly during this process. after 2 weeks, they were treated 2 days a week until the 6th week by meeting with the physiotherapist in real time via the Albert Health Assistant application. In the remaining days, they were asked to follow the exercise videos uploaded to the Albert system, it will be checked whether they have done the daily exercises, and a daily reminder message will be sent through the system.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: asynchronized telerehabilitation
Description: The exercise program for the asynchronized telerehabilitation group will be uploaded to the Albert Health Assistant in the form of 2-week programs in video form from the first Day. Whether the patients apply these videos on a daily basis will be checked through the system, a message reminding the daily routine exercise program will be sent through the system.
Study: NCT05766956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced Care at Home (ACH)
Description: Inpatient hospitalization offered in the home setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Brick-and-Mortar Hospitalization
Description: Inpatient hospitalization offered in the hospital setting.
Study: NCT05875480

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supervised (face to face) rehabilitation
Description: In the supervised physiotherapy group, the exercise program of the first 2 weeks was submitted via Albert Health Assistant application and patients were asked to do these exercises regularly during this process. After 2 weeks, they attended the rehabilitation program in the physical therapy department of the hospital accompanied by a physiotherapist, starting from the 14th postoperative day, 2 days a week until the 6th week. The ROM, pain, functional and general health evaluations of the patients in this group were carried out on the online platform. In addition, on the days when they did not come to treatment, their daily routine exercises were followed through the Albert system.
Study: NCT05769270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Navigation and Coping Skills
Description: Participants will receive 6 sessions of peer navigation and coping skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Participants will receive referrals for PrEP and services

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Treatment as Usual
Description: Participants will receive referrals for PrEP and services
Study: NCT05967286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scans

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05580289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: half-shower and hot pack
Description: The patients in the experimental group will be given hot application and half shower applications and the pain levels of the patients and the development of bladder retention will be followed.
Study: NCT05794529

Intervention type: OTHER
Intervention: There are no interventions in the present study
Description: There are no interventions in the present study
Study: NCT05967286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05080829

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Myeloid mutations measurement
Description: Measure of myeloid mutations by NGS when detection of refractory or relapsed CML is done
Study: NCT05286294

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT)
Description: Fecal Microbiota Transplant (FMT)
Study: NCT04754711

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement
Description: We will propose to the patients of group 1 several different oral nutritional supplements according to taste, and consistency of each child in order to optimize observance. Each of those different oral nutritional supplements will be adapted to the nutritional survey and the age of children without exceeding recommended intake of proteins, carbohydrates, lipids and micronutrients. Those patients will consume the Oral Nutritional Supplement during 12 months.
Study: NCT05619926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0601 for Injection
Description: Intravenous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0601 for Injection
Description: Intravenous Injection
Study: NCT06319911

Intervention type: DEVICE
Intervention: AETOS
Description: The AETOS Shoulder System will be implanted into the right or left shoulder in the anatomic or reverse configuration

Intervention type: DEVICE
Intervention: AETOS
Description: The AETOS Shoulder System will be implanted into the right or left shoulder in the anatomic or reverse configuration
Study: NCT05325164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine
Study: NCT06482060

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stabilization splint
Description: Stabilization splint application is a treatment that improves the function of TMJ and masticatory muscles by creating a balanced, stable occlusion to reduce the effects of occlusal interference and parafunctional habits and eliminate associated pain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stabilization splint
Description: Stabilization splint application is a treatment that improves the function of TMJ and masticatory muscles by creating a balanced, stable occlusion to reduce the effects of occlusal interference and parafunctional habits and eliminate associated pain.
Study: NCT06153381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: Rehabilitation program based on standard care, but assisted via an instant messaging application using a personal smartphone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard car
Description: Rehabilitation program based on standard care, assisted with one education session plus informative brochure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard car
Description: Rehabilitation program based on standard care, assisted with one education session plus informative brochure
Study: NCT05967286

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT05934981

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery under low pressure and warm and humidified CO2 Insufflation
Description: low pressure pneumoperitoneum (5-7mmHg) and use warm (35°C), humidified (95% relative humidity) CO2 insufflation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic surgery under low pressure and conventional Insufflation
Description: low pressure pneumoperitoneum (5-7mmHg), and use standard room temperature with dry insufflation.
Study: NCT05786573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obexelimab
Description: Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obexelimab
Description: Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04370509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (VEGF-TKI)
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Nephrectomy (CN)
Description: Undergo CN

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Nephrectomy (CN)
Description: Undergo CN

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy (MET)
Description: Undergo MET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy (MET)
Description: Undergo MET

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05745493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Engage Coaching (S-ENG)
Description: Social Engage Coaching (S-ENG) involves 10 individual coaching sessions focused on increasing social connection. S-ENG is a stepped, modular intervention that was developed to allow personalization to a given subject's needs, preferences, and individualized barriers to social connection. Early sessions include psychoeducation on the importance of social connection; a values clarification exercise on aspects of connection most important to subjects; and assessment of current social networks and social activities. Together, the coach and subject create a conceptualization of reasons for loneliness and identify personalized activities most likely to impact loneliness. The primary activity is 'action planning,' which involves selecting a social goal for the week, brainstorming ways to meet the goal, identifying barriers, and selecting specific actions to take before the next session. The first 8 sessions are offered weekly and the final two are monthly booster sessions.
Study: NCT05281861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zirconia reinforced Lithium disilicate (Vita Ambria) ceramic onlay restoration
Description: In experimental group, Participants will be restored with onlay ceramic restorations constructed from zirconia reinforced Lithium disilicate (Vita Ambria) glass ceramic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lithium disilicate (IPS e-max press) ceramic onlay restoration
Description: In control group, Participants will be restored with onlay ceramic restorations constructed from Lithium disilicate (IPS e-max press) glass ceramic